factor VIIIa

Factor VIII circulates in plasma bound to von Willebrand factor (vWF), which stabilizes it and protects it from premature degradation. Upon vascular injury, thrombin (and to a lesser extent factor Xa) cleaves factor VIII to its activated form, factor VIIIa, releasing it from vWF. Factor VIIIa then serves as a cofactor for factor IXa, forming the intrinsic tenase complex on phospholipid surfaces (e.g., activated platelets) in the presence of calcium ions. This complex activates factor X to Xa at a rate approximately 200,000-fold faster than factor IXa alone, representing a critical amplification step in the coagulation cascade. Factor VIIIa is eventually inactivated by activated protein C (APC) in conjunction with protein S, providing a regulatory checkpoint to limit clot propagation. Clinically, deficiency of factor VIII (congenital, X-linked recessive) causes Hemophilia A, the most common severe inherited bleeding disorder, presenting with hemarthroses, deep tissue hematomas, and prolonged aPTT (which corrects with mixing studies) but normal PT and bleeding time. Acquired factor VIII deficiency can result from autoantibodies (acquired hemophilia). Recombinant factor VIII concentrates are used for replacement therapy, and some patients develop neutralizing inhibitors against infused factor VIII, complicating treatment and requiring bypassing agents (e.g., recombinant factor VIIa, activated prothrombin complex concentrates) or emicizumab (a bispecific antibody mimicking factor VIIIa function by bridging factors IXa and X).